Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL(+) leukemic cells and induces apoptosis

被引:253
|
作者
GambacortiPasserini, C
leCoutre, P
Mologni, L
Fanelli, M
Bertazzoli, C
Marchesi, E
DiNicola, M
Biondi, A
Corneo, GM
Belotti, D
Pogliani, E
Lydon, NB
机构
[1] IST NAZL TUMORI,DIV EXPT ONCOL D & MED ONCOL C,I-20133 MILAN,ITALY
[2] UNIV MILAN,S GERARDO HOSP,SECT HEMATOL,MONZA,ITALY
[3] UNIV MILAN,S GERARDO HOSP,DIV PEDIAT HEMATOL,MONZA,ITALY
[4] IST EUROPEO ONCOL,DIV EXPT ONCOL,MILAN,ITALY
[5] NOVARTIS INT INC,ONCOL RES DEPT,BASEL,SWITZERLAND
关键词
BCR/ABL; CML; ALL; tyrosine kinase inhibitors; apoptosis;
D O I
10.1006/bcmd.1997.0155
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The BCR/ABL fusion protein transforms myeloid stem cells. Both chronic myelogenous leukemias (CML) and a subset of acute lymphoblastic leukemias (ALL) are associated with the expression of BCR/ABL proteins. This knowledge has nor yet been translated into any specific tool to control ABL driven neoplastic cells growth, CGP57148B is an ATP-competitive inhibitor of the ABL protein kinase; it has been shown to inhibit the kinase activity of ABL both in vitro and in vivo and to inhibit the growth of v-abl and bcr/abl transfectants, as well as the in vitro formation of bone marrow (BM)-derived colonies in the presence of growth factors in some CML patients. These studies were performed to investigate the activity of CGP57148B on the spontaneous proliferation of both fresh and cultured, leukemic and normal, BCR/ABL positive and negative cells, and to study its mechanism of action. Six cell lines derived from BCR/ABL+ leukemias (K562, BV173, KCL22, KU812, MC3, LAMA84), thirteen BCR/ABL negative lines, both neoplastic(KG1, SU-DHL-1, U937, Daudi, NB4, NB4.306) and derived from normal cells (PHA blasts, LAK, fibroblasts, LCL, renal epithelial cells, endothelial cells, CD34(+) cells), and 14 fresh leukemic samples were tested using a tritiated thymidine uptake assay. The in vivo phosphorylation of the BCR/ABL protein was evaluated by western blot, while apoptosis was detected by the annexin V/propidium binding test. The induction of differentiation was assayed by immunofluorescence using multiple antibodies. All six BCR/ABL(+) lines showed a dose dependent inhibition of their spontaneous proliferative rate, which was not accompanied by differentiation. The treatment caused, within minutes, dephosphorylation of the BCR/ABL protein, followed in 16-24 hours by a decrease in cycling cells and induction of apoptosis, No significant inhibition of DNA synthesis was observed in any BCR/ABL negative normal or neoplastic line at concentrations less than or equal to 3 mu M, with the exception of fibroblasts and CD34 cells, Proliferation inhibition was observed also when using fresh samples obtained from two Ph+ ALL and 12 consecutive CML patients. Induction of apoptosis was observed in these samples too. The activity of CGP57148B can be monitored in ex vivo isolated or cultured cells using a simple and reproducible assay, without the need for exogenously added growth factors. This molecule possibly exerts its effects through the inhibition of the kinase activity of BCR/ABL and the subsequent initiation of apoptosis, without inducing cell differentiation. Some normal cells are also affected.
引用
收藏
页码:380 / 394
页数:16
相关论文
共 50 条
  • [11] The immunogenicity of Bcr-Abl-expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl-regulated antigens
    Scheich, Florian
    Duyster, Justus
    Peschel, Christian
    Bernhard, Helga
    BLOOD, 2007, 110 (07) : 2556 - 2560
  • [12] Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells
    Fernandez-Luna, JL
    APOPTOSIS, 2000, 5 (04) : 315 - 318
  • [13] Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells
    J. L. Fernandez-Luna
    Apoptosis, 2000, 5 : 315 - 318
  • [14] Inhibition of Bcr-Abl tyrosine kinase sensitizes cells to sapacitabine
    Jiang, Yingjun
    Liu, Xiaojun
    Chestang, Adrienne
    Plunkett, William
    CANCER RESEARCH, 2014, 74 (19)
  • [15] Sorafenib Induces Apoptosis Specifically in Cells Expressing BCR/ABL by Inhibiting Its Kinase Activity to Activate the Intrinsic Mitochondrial Pathway
    Kurosu, Tetsuya
    Ohki, Manabu
    Wu, Nan
    Kagechika, Hiroyuki
    Miura, Osamu
    CANCER RESEARCH, 2009, 69 (09) : 3927 - 3936
  • [16] Inhibition of Bcr–Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells
    Mei Huang
    Jay F Dorsey
    PK Epling-Burnette
    Ramadevi Nimmanapalli
    Terry H Landowski
    Linda B Mora
    Guilian Niu
    Dominic Sinibaldi
    Fanqi Bai
    Alan Kraker
    Hua Yu
    Lynn Moscinski
    Sheng Wei
    Julie Djeu
    William S Dalton
    Kapil Bhalla
    Thomas P Loughran
    Jie Wu
    Richard Jove
    Oncogene, 2002, 21 : 8804 - 8816
  • [17] Inhibition of apoptosis by downregulation of hBex1, a novel mechanism, contributes to the chemoresistance of Bcr/Abl+ leukemic cells
    Ding, Kefeng
    Su, Yanyan
    Pang, Lingrong
    Lu, Qinghua
    Wang, Zhanhuai
    Zhang, Suzhan
    Zheng, Shu
    Mao, Jianshan
    Zhu, Yongliang
    CARCINOGENESIS, 2009, 30 (01) : 35 - 42
  • [18] Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors
    D K Hiwase
    D L White
    J A Powell
    V A Saunders
    S A Zrim
    A K Frede
    M A Guthridge
    A F Lopez
    R J D'Andrea
    L B To
    J V Melo
    S Kumar
    T P Hughes
    Leukemia, 2010, 24 : 771 - 778
  • [19] SUCCESSFUL CO-TREATMENT OF BCR-ABL LEUKEMIC CELLS WITH PONATINIB, AN ABL KINASE INHIBITOR, AND VORINOSTAT, A HISTONE DEACETYLASE INHIBITOR: A POTENTIAL TREATMENT FOR BCR-ABL POSITIVE LEUKEMIA CELLS
    Okabe, S.
    Tauchi, T.
    Kimura, S.
    Maekawa, T.
    Ohyashiki, K.
    HAEMATOLOGICA, 2012, 97 : 210 - 210
  • [20] Short-term intense Bcr–Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL+ cells
    D K Hiwase
    D L White
    V A Saunders
    S Kumar
    J V Melo
    T P Hughes
    Leukemia, 2009, 23 : 1205 - 1206